Daiichi Hit With $41.8M Verdict In Cancer Drug IP Fight
A Texas federal jury found on Friday that Daiichi Sankyo Co. Ltd. owes $41.8 million in damages because a breast cancer treatment medication it markets under the brand name Enhertu infringes...To view the full article, register now.
Already a subscriber? Click here to view full article